Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
about
The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophreniaAripiprazole: from pharmacological profile to clinical useAn intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismDopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FutureEffects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPAReversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.Is the PANSS used correctly? a systematic review.Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.Pathway-Specific Dopamine Abnormalities in Schizophrenia.Neuroimaging in psychiatric disordersEvaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia.18F-fallypride binding potential in patients with schizophrenia compared to healthy controlsRelationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationshipStriatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response.Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.Antipsychotic occupancy of dopamine receptors in schizophrenia.The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia.Presynaptic dopamine in schizophrenia.How have developments in molecular imaging techniques furthered schizophrenia research?Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole.A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.The Harms of Antipsychotic Drugs: Evidence from Key Studies.In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse.Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
P2860
Q24608243-F1D3C196-72CE-48E0-8970-7158374639A5Q26778312-9D93E5DB-0628-48E2-8BCA-A44E9AF76009Q27491346-B97F7BF7-0879-4BD5-AEAC-3B714C720EB0Q28084069-06A8BD39-7FBD-4D6D-B8B3-8126E5F1CCA3Q28394341-36A6AAF6-E14E-49DE-B808-347317D8149BQ28484113-AD47D7F2-1D2B-479D-8F9F-0499F8F3F330Q33708210-92BDC94C-733E-48B9-B336-18E240081D8CQ33964357-341B0CF3-70EA-474E-98E7-B3BE44A8FF90Q34187457-7E390789-E27A-4550-A69C-6D6E68CEF62CQ34527656-49749A92-3A84-46D6-BE47-C5A2DB86D716Q34644697-DA21E2BA-5B88-4454-BC41-E2FD19E0D239Q35103315-4E9092C1-A337-4BA5-BE01-B80D7D6CD6B3Q35550864-BC0F5A24-A652-4B26-BCB1-FA45DC51EE41Q35752862-7D8C4485-13BB-4026-8DBD-EEBE7042DBC6Q35847706-A886C4FD-CE75-4CDC-B538-A4BC5B644FDAQ35866868-B4118E93-74BE-40FA-A2AD-96880FA4C344Q35950793-E1F9C10F-365E-4B9D-BB4C-7F3BDB9110AAQ36015452-B183DDDF-97F8-4A03-987E-E1233AADD5C9Q36382450-CDDCEB46-DDBD-4784-B6AA-F17E87F98FF8Q36994341-E457AE17-2299-415E-8C76-22AA91B870A0Q37531716-227D1710-6AE0-4F63-A3C9-BEC60D52B511Q37633750-F5DA91CF-1F33-44CA-87BF-833E78220910Q37818511-80E1B1A8-987C-4288-95B8-6058612E447AQ37820985-1DC0F2E5-26F3-4412-8143-6CD83714A718Q37825635-C9B734BE-59B5-4F74-B1C5-F75EEAF282C7Q37829639-AB46335B-8E42-4D81-93CE-CE901E08D49FQ37970762-8742917F-28E2-4DD4-9FD5-3B8C0CD4B4C6Q37983747-CE0F6447-5BEB-4632-A797-0C6463EF12FAQ38667647-28EC2DE8-9FF4-47D3-BBD0-F6F5EA344125Q38740848-8B32BB02-61AE-4738-A017-E319C82B37BDQ38844790-2BC35F7C-7FE1-4666-B440-E414C0EBBED5Q39210357-7F47B799-99AD-4946-8D79-D1636D842655Q39326557-AC861EA5-8E09-4E65-A289-FAD99B0EA5EDQ39959170-BEF29030-7AB3-47AB-B0EB-9A22FB9F6E32Q40467111-7ADCF294-1E7D-4479-9E78-4024522FE380Q41909369-D3AD91AE-4640-46EE-9B72-7A9A2043FE9FQ41918764-66A9601A-22CD-4F62-B91D-0C92050A32F4Q42652786-062890CE-2754-456F-850A-25718B287AA9Q43922950-14940DFD-2312-48E2-B391-38F64748CA6FQ44009699-954C1F1B-D482-4E78-A79C-F245C0CDD8A2
P2860
Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@ast
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@en
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@nl
type
label
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@ast
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@en
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@nl
prefLabel
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@ast
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@en
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@nl
P2093
P2860
P921
P356
P1476
Dose-occupancy study of striat ...... with PET and [18F]fallypride.
@en
P2093
Beatriz Alvarez
Elizabeth Hackett
Jong-Hoon Kim
Lawrence S Kegeles
Marc Laruelle
Mark Slifstein
Roberto Gil
Robyn Gonzales
Sung-A Bae
W Gordon Frankle
P2860
P2888
P304
P356
10.1038/NPP.2008.33
P407
P577
2008-04-16T00:00:00Z
P5875
P6179
1011713834